Evidence map›Paper›PMID 41542468›Full record

ArticlebioRxiv : the preprint server for biology2026

Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synuclein.

Aslam Uddin, Eugene Serebryany

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aslam UddinDepartment of Physiology and Biophysics, Stony Brook University, SUNY, Stony Brook, NY, USA.
Eugene SerebryanyDepartment of Physiology and Biophysics, Stony Brook University, SUNY, Stony Brook, NY, USA.ORCID 0000-0003-1066-7143

Funding

High-throughput disulfide and FRET scanning to reveal protein conformational ensembles in vitro and in vivo.R00GM141459 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Evgeny Serebryany · 2024 to 2026
$747k
NIGMS NIH HHS R00 GM141459
6 · The paper itself

Abstract

Intrinsically disordered proteins can aggregate in many distinct conformations (polymorphs). Polymorphs are a striking example of fold-switching: one primary structure able to form distinct tertiary structures. Distinct polymorphs can yield distinct molecular, cellular, and disease phenotypes. Disulfide crosslinks canalize disordered proteins into distinct regions of the conformational landscape, even if the monomer remains disordered. Human α-synuclein is a disordered, natively Cys-free protein involved in synaptic transmission. Its amyloid aggregation is implicated in Parkinson's disease and other synucleinopathies. Recent cryo-EM fibril structures have revealed distinct classes of amyloid polymorphs that wild-type human α-synuclein can adopt. We created three double-Cys α-synuclein variants predicted to form intramolecular disulfide bridges compatible with known amyloid polymorphs, plus three other double-Cys variants at arbitrary positions as controls. We purified all six variants as intramolecularly disulfide-crosslinked monomers in solution. Two of the three predicted pro-aggregation variants formed amyloid fibrils as expected, and two of the three control variants did not. Surprisingly, one of the controls formed amyloid fibrils with a distinctive morphology by negative-stain TEM, suggesting the possibility of a previously unknown polymorph. Conversely, the crosslinked variant that failed to aggregate as expected showed sub-stoichiometric, dose-dependent anti-aggregation activity, strongly suppressing amyloid formation by wild-type α-synuclein.

Indexed as

amyloiddisulfide bonddisulfide engineeringpolymorphprotein aggregationα-synuclein

Identifiers

PMID41542468
PMCPMC12803154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.